Kruger Products delays new TAD tissue plant as Q3 earnings rise
Kruger Products has pushed the start-up of its planned through-air-dried (TAD) tissue facility beyond 2028 and deferred a final location decision until the economic and trade outlook is clearer. Third-quarter 2026 adjusted EBITDA rose 9.1% to USD 65.4m (CAD 93.5m) on revenue up 5.1% at USD 412.7m (CAD 589.7m), according to results from KP Tissue, which holds 12.0% of Kruger Products. Kruger expects fourth-quarter adjusted EBITDA slightly below the third quarter but above the prior-year period.
Why this mattersPushing new TAD capacity beyond 2028 slows premium tissue supply growth in North America, with Kruger citing trade uncertainty despite rising earnings.
- The new TAD facility will not start operations in 2028 as planned; the location decision is deferred
- Q3 2026 adjusted EBITDA rose 9.1% to USD 65.4m (CAD 93.5m) from USD 60.0m (CAD 85.7m)
- Q3 2026 revenue rose 5.1% to USD 412.7m (CAD 589.7m) from USD 392.7m (CAD 561.1m)
- Q3 net income rose to USD 19.4m (CAD 27.7m) from USD 10.2m (CAD 14.6m)
- Nine-month 2026 adjusted EBITDA rose 15.8% to USD 189.6m (CAD 271.0m)
- Q4 2026 adjusted EBITDA is expected slightly below Q3 but above Q4 2025, assuming a similar tariff environment